Literature DB >> 15306664

Chronic myelogenous leukemia--identifying the hydra's heads.

Michael F Clarke1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15306664     DOI: 10.1056/NEJMp048120

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  2 in total

1.  Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.

Authors:  Prithviraj Bose; Edward B Perkins; Connie Honeycut; Martha D Wellons; Tammy Stefan; James W Jacobberger; Emmanouil Kontopodis; Jan H Beumer; Merrill J Egorin; Chiyo K Imamura; W Douglas Figg; Judith E Karp; Omer N Koc; Brenda W Cooper; Selina M Luger; A Dimitrios Colevas; John D Roberts; Steven Grant
Journal:  Cancer Chemother Pharmacol       Date:  2012-02-15       Impact factor: 3.333

Review 2.  Leukemia stem cells.

Authors:  Ling Luo; Zhong Chao Han
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.